Hosted on MSN2mon
Reactive cysteines on peptide antigens may unlock new cancer immunotherapy possibilities
Northwestern Medicine scientists have developed a method for identifying reactive cysteines on peptide antigens within ... as antibody-dependent cellular phagocytosis, which could serve as a ...
Nature4y
Carisma drives CAR-M engineered macrophage cancer therapy forward
activating nearby antigen presenting cells (APCs), notably dendritic cells (DCs), and repolarizing tumor-associated macrophages (TAMs) toward an M1 phenotype. In addition to direct phagocytosis of ...
Targeted Oncology5d
FDA Clears IND Application for LTZ-301 in non-Hodgkin Lymphoma
The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...
Business Wire5d
LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301
FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.